BioSpace News Archive

Rocket Pharmaceuticals, Inc. announces the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $17.50 per share.

SpeeDx is the First Trusted Reagent Manufacturer to launch a new test for use on the GeneXpert® System

Hansa Biopharma AB announced that its Annual Report for 2018 is now available on the company’s website, www.hansabiopharma.com

CStone Pharmaceuticals announced that the National Medical Products Administration recently approved the initiation of a Phase I/II clinical trial in China evaluating avapritinib, a drug candidate discovered by the company’s partner Blueprint Medicines, in patients with unresectable or metastatic gastrointestinal stromal tumors.

Hansa Biopharma AB announced that it received Clinical Trial Application and Ethics Committee approvals in Europe for the company’s Phase 2 study of imlifidase in Guillain Barré Syndrome.

Interim safety results and early efficacy signals with HepaStem bode well for subsequent confirmatory trials in ACLF and provide valuable insights for imminent start of clinical evaluation in NASH

The shareholders in IRRAS AB (publ), reg. no. 556872-7134, are hereby invited to attend the annual general meeting (“AGM”) to be held on Tuesday 14 May 2019 at 12.00 noon at IVA Konferenscenter, Grev Turegatan 16 in Stockholm, Sweden.

As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share experiences of the beyond the visible impact of living with this distressing skin disease

Ascletis Pharma Inc. announces that according to the official notifications from Zhejiang Provincial Medical Insurance Bureau, Zhejiang Provincial Department of Finance and Zhejiang Provincial Health Committee, the “Basic Medical Insurance -- Reimbursement-by-disease for outpatients with Hepatitis C” program will be launched in Zhejiang Province.

TA Associates, a leading global growth private equity firm, announced that it has completed a significant minority investment in Indira IVF, a leading India-based infertility treatment provider.